E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
|
E.1.1.1 | Medical condition in easily understood language |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Virus Diseases [C02] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 20.0 |
E.1.2 | Level | HLGT |
E.1.2 | Classification code | 10047438 |
E.1.2 | Term | Viral infectious disorders |
E.1.2 | System Organ Class | 10021881 - Infections and infestations |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To assess if 10 doses of HC, each taken 12 hours apart, increase the proportion of COVID-19 patients who have a negative nasopharyngeal RT-PCR for SARS-CoV-2 by day 7 post diagnosis in the HC arm compared to the no-HC arm. |
|
E.2.2 | Secondary objectives of the trial |
Secondary objective 1: To assess the safety of HC in COVID-19 patients treated in the ambulatory setting Secondary objective 2: To assess the clinical efficacy of HC in COVID-19 patients Secondary endpoint 3:To assess if 10 doses of HC, each taken 12 hours apart, increase the proportion of COVID-19 patients who have a negative COVIDAM, Protocol version 3.0, dated 16/April/2020 9/49 nasopharyngeal RT-PCR for SARS-CoV-2 by day 7 post onset of symptoms (POS) in the HC arm compared to the no-HC arm. Secondary Objective 4: To assess if 10 doses of HC, each taken 12 hours apart, increase the proportion of COVID-19 patients who have a negative nasal AND salivary RT-PCR for SARS-CoV-2 by day 7 post diagnosis in the HC arm compared to the no-HC arm. |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
- Aged ≥ 18 and < 65 years old - Confirmed symptomatic or asymptomatic COVID-19 as defined by a laboratory diagnosis of SARS-CoV-2 on a respiratory sample within the previous 72 hours - If symptomatic, having COVID-19 symptoms since less than 72 hours (cough, throat ache, fever, dyspnea) at the time of enrollment. - Able and willing to provide written informed consent. - Able to safely attend, with individual transportation, scheduled follow-up visits at ITM.
|
|
E.4 | Principal exclusion criteria |
- Need of hospitalization before or at enrollment visit (visit 1) - Known contra-indication to HC (hypersensitivity to 4-aminoquinoline compounds, ocular retinopathy, epilepsy, diabetes) - Pregnancy or breast-feeding - Use of any other (experimental) drug aiming to treat COVID-19 - Use of any treatment with potential interaction with HC and flagged “red” or “orange” in the list of drug interactions published on the reference website http://www.covid19-druginteractions.org/ (accessed on 30/03/2020). This is a dynamic list which is being updated as new information becomes available. The most recent update of the list will be used. Antacids are flagged orange but can be used if taken at least 4h before or 4h after HC.
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
proportion of participants with a negative nasopharyngeal sample* by day 7 post diagnosis * defined by a negative RT-PCR on a nasopharyngeal swab of two subsequent study visits. The date of the first negative sample will then be taken as the date of negativity
|
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
|
E.5.2 | Secondary end point(s) |
Secondary endpoint 1: frequency and pattern of reported adverse events, adverse reactions, Serious Adverse Events, Serious adverse reactions, and SUSARs.. Secondary endpoint 2: pattern and duration of clinical symptoms, as reported by the patients; rate of hospital admission during follow-up. Secondary endpoint 3: proportion of participants with a negative nasopharyngeal sample* by day 7 POS * defined by a negative RT-PCR on a nasopharyngeal swab of two subsequent study visits. The date of the first negative sample will then be taken as the date of negativity Secondary endpoint 4: proportion of participants with a negative nasal swab + saliva sample* by day 7 post diagnosis * defined by a negative RT-PCR on a self-taken nasal swab AND saliva sample of two subsequent study visits. The date of the first pair of negative samples will then be taken as the date of negativity |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
Secondary endpoint 1: visit 2 (day 3), visit 3 (day 6), visit 4 (day 9), visit 5 (day 13) ,visit 6 (day 17) and visit 7 (day 21) Secondary endpoint 2: visit 2 (day 3), visit 3 (day 6), visit 4 (day 9), visit 5 (day 13) ,visit 6 (day 17) and visit 7 (day 21) Secondary endpoint 3: Day 7 Post onset of symptoms Secondary endpoint 4: Day 7 post diagnosis |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | Yes |
E.8.2.3.1 | Comparator description |
|
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| Yes |
E.8.4 | The trial involves multiple sites in the Member State concerned | No |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | |
E.8.9.1 | In the Member State concerned months | 5 |
E.8.9.1 | In the Member State concerned days | |